- Endoscopic retrograde cholangiopancreatography (ERCP) devices, designed for the diagnosis and treatment of biliary and pancreatic ductal systems, are increasingly vital components of modern gastroenterology practices in both hospital and specialty clinic settings due to their enhanced precision, minimal invasiveness, and ability to combine diagnostic imaging with therapeutic intervention
- The escalating demand for ERCP devices is primarily fueled by the rising prevalence of pancreatic and biliary diseases, increasing geriatric population, and growing preference for minimally invasive procedures among patients and healthcare providers
- North America dominated the endoscopic retrograde cholangiopancreatography devices market with the largest revenue share of 41.6% in 2024, characterized by early adoption of advanced endoscopic technologies, high healthcare expenditure, and a strong presence of leading manufacturers. The U.S. experienced substantial growth in ERCP procedures, particularly within outpatient surgical centers and specialty hospitals, driven by innovations in device design and integration with imaging technologies
- Asia-Pacific is expected to be the fastest growing region in the endoscopic retrograde cholangiopancreatography devices market during the forecast period, with a projected CAGR of 8.9%, fueled by improving healthcare infrastructure, rising medical tourism, and increased awareness regarding gastrointestinal health in countries such as China, India, and Japan
- The bile duct segment dominated the endoscopic retrograde cholangiopancreatography devices with a market revenue share of 41.3% in 2024, driven by high procedure volumes for gallstone removal and malignancy treatments
